Comparing two immunotherapy drugs after melanoma surgery
Part of Cancer, Skin clinical trials.
This study compares two immunotherapy drugs to see which is better at preventing melanoma from returning after surgery. One drug is an experimental biosimilar similar to Keytruda, and the other is Keytruda itself.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You had surgery to completely remove your melanoma (skin cancer) and there is no sign of it spreading.
- Your melanoma was stage IIB, IIC, or III.
- You are in good physical condition (able to do your normal daily activities).
- You have not had treatment for your melanoma after surgery, and you have not had certain prior cancer treatments.
- You do not have active autoimmune disease requiring treatment, or you have not needed high-dose steroids recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a biosimilar drug (AVT32-DRL_PB) to see how it compares to the approved immunotherapy Keytruda® in people whose melanoma has been fully removed by surgery. It aims to help prevent the cancer from coming back.
This trial tests whether a new biosimilar drug (Bmab1700) works as well as the approved immunotherapy Opdivo (nivolumab) to prevent melanoma from coming back after surgery. You would receive either the biosimilar or Opdivo for about a year, and researchers will compare how your body handles the drug and its safety.
This trial tests two immunotherapy drugs, ipilimumab and nivolumab, given before surgery for people whose melanoma has come back after previous anti-PD1 treatment. The goal is to see if this combination can shrink the tumor and help prevent future recurrence.
This trial tests whether giving a shorter course of immunotherapy after surgery can help prevent melanoma from coming back. It is for people with high-risk melanoma who have had the cancer fully removed.
This trial tests whether giving pembrolizumab (Keytruda) before surgery helps people with a certain type of advanced melanoma (stage IIb/c). The goal is to see if this treatment can improve outcomes before the tumor is removed.
This trial tests whether giving immunotherapy before surgery and possibly skipping some after may help people with advanced but removable melanoma. It aims to see if this approach can reduce the chance of the cancer coming back.
Hear when a new Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.